Abstract

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults.

 July 2018: The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. For more information, see the summary of product characteristics for atezolizumab.

There is separate guidance on atezolizumab for people who have had cisplatin-based chemotherapy.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: More evidence on atezolizumab is being collected, until December 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Commercial arrangement

There is a managed access agreement, which includes a patient access scheme for atezolizumab. Contact Welwyn.rx_bdop@roche.com for details.